NCT04181645View on ClinicalTrials.gov

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 29, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

May 1, 2023

Conditions
Pancreatic Cancer Stage IV
Interventions
DRUG

Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection

Trial Locations (1)

200127

RenJiH, Shanghai

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

RenJi Hospital

OTHER

NCT04181645 - SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter